JOHNSON & JOHNSON
JNJAPI behind this page
JNJ Q3 2025 request
Playground key active
/api/financials?ticker=JNJ&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 23,993 | 22,471 | +6.8% |
Show Product Lines breakouts |
|||
| ADVANCED · MEDTECH | 477 | 448 | +6.5% |
| ADVANCED · MEDTECH | 688 | 661 | +4.1% |
| ADVANCED · MEDTECH | 1,165 | 1,109 | +5.0% |
| CAPLYTA · Innovative Medicine | 240 | — | — |
| CAPLYTA · Innovative Medicine | 240 | — | — |
| CARVYKTI · Innovative Medicine | 396 | 258 | +53.5% |
| CARVYKTI · Innovative Medicine | 128 | 27 | +374.1% |
| CARVYKTI · Innovative Medicine | 524 | 286 | +83.2% |
| CONCERTA / methylphenidate · Innovative Medicine | 14 | 26 | -46.2% |
| CONCERTA / methylphenidate · Innovative Medicine | 127 | 117 | +8.5% |
| CONCERTA / methylphenidate · Innovative Medicine | 140 | 142 | -1.4% |
| CONTACT LENSES / OTHER · MEDTECH | 456 | 441 | +3.4% |
| CONTACT LENSES / OTHER · MEDTECH | 562 | 527 | +6.6% |
| CONTACT LENSES / OTHER · MEDTECH | 1,018 | 968 | +5.2% |
| DARZALEX · Innovative Medicine | 2,088 | 1,684 | +24.0% |
| DARZALEX · Innovative Medicine | 1,584 | 1,332 | +18.9% |
| DARZALEX · Innovative Medicine | 3,672 | 3,016 | +21.8% |
| EDURANT/rilpivirine · Innovative Medicine | 7 | 8 | -12.5% |
| EDURANT/rilpivirine · Innovative Medicine | 378 | 323 | +17.0% |
| EDURANT/rilpivirine · Innovative Medicine | 385 | 330 | +16.7% |
| ERLEADA · Innovative Medicine | 378 | 337 | +12.2% |
| ERLEADA · Innovative Medicine | 558 | 453 | +23.2% |
| ERLEADA · Innovative Medicine | 936 | 790 | +18.5% |
| GENERAL · MEDTECH | 555 | 535 | +3.7% |
| GENERAL · MEDTECH | 823 | 791 | +4.0% |
| GENERAL · MEDTECH | 1,378 | 1,325 | +4.0% |
| HIPS · MEDTECH | 262 | 250 | +4.8% |
| HIPS · MEDTECH | 144 | 131 | +9.9% |
| HIPS · MEDTECH | 405 | 381 | +6.3% |
| IMBRUVICA · Innovative Medicine | 211 | 259 | -18.5% |
| IMBRUVICA · Innovative Medicine | 483 | 494 | -2.2% |
| IMBRUVICA · Innovative Medicine | 695 | 753 | -7.7% |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA · Innovative Medicine | 664 | 780 | -14.9% |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA · Innovative Medicine | 267 | 269 | -0.7% |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA · Innovative Medicine | 929 | 1,049 | -11.4% |
| KNEES · MEDTECH | 216 | 212 | +1.9% |
| KNEES · MEDTECH | 160 | 140 | +14.3% |
| KNEES · MEDTECH | 377 | 352 | +7.1% |
| OPSUMIT/OPSYNVI · Innovative Medicine | 409 | 417 | -1.9% |
| OPSUMIT/OPSYNVI · Innovative Medicine | 168 | 166 | +1.2% |
| OPSUMIT/OPSYNVI · Innovative Medicine | 578 | 583 | -0.9% |
| OTHER IMMUNOLOGY · Innovative Medicine | 12 | 1 | +1100.0% |
| OTHER IMMUNOLOGY · Innovative Medicine | 0 | 0 | — |
| OTHER IMMUNOLOGY · Innovative Medicine | 12 | 1 | +1100.0% |
| OTHER INFECTIOUS DISEASES · Innovative Medicine | 4 | 3 | +33.3% |
| OTHER INFECTIOUS DISEASES · Innovative Medicine | 42 | 54 | -22.2% |
| OTHER INFECTIOUS DISEASES · Innovative Medicine | 47 | 56 | -16.1% |
| OTHER NEUROSCIENCE · Innovative Medicine | 46 | 46 | 0.0% |
| OTHER NEUROSCIENCE · Innovative Medicine | 210 | 235 | -10.6% |
| OTHER NEUROSCIENCE · Innovative Medicine | 256 | 281 | -8.9% |
| Other Oncology · Innovative Medicine | 56 | 36 | +55.6% |
| Other Oncology · Innovative Medicine | 39 | 50 | -22.0% |
| Other Oncology · Innovative Medicine | 94 | 86 | +9.3% |
| Other · Innovative Medicine | 115 | 121 | -5.0% |
| Other · Innovative Medicine | 13 | 21 | -38.1% |
| Other · Innovative Medicine | 149 | 170 | -12.4% |
| Other · Innovative Medicine | 39 | 39 | 0.0% |
| Other · Innovative Medicine | 264 | 292 | -9.6% |
| Other · Innovative Medicine | 53 | 60 | -11.7% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 315 | 355 | -11.3% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 81 | 94 | -13.8% |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA · Innovative Medicine | 397 | 449 | -11.6% |
| REMICADE · Innovative Medicine | 326 | 281 | +16.0% |
| REMICADE · Innovative Medicine | 19 | 27 | -29.6% |
| REMICADE · Innovative Medicine | 132 | 112 | +17.9% |
| REMICADE · Innovative Medicine | 476 | 419 | +13.6% |
| RYBREVANT + LAZCLUZE · Innovative Medicine | 136 | 68 | +100.0% |
| RYBREVANT + LAZCLUZE · Innovative Medicine | 61 | 21 | +190.5% |
| RYBREVANT + LAZCLUZE · Innovative Medicine | 198 | 89 | +122.5% |
| SIMPONI / SIMPONI ARIA · Innovative Medicine | 309 | 299 | +3.3% |
| SIMPONI / SIMPONI ARIA · Innovative Medicine | 377 | 218 | +72.9% |
| SIMPONI / SIMPONI ARIA · Innovative Medicine | 687 | 516 | +33.1% |
| SPINE, SPORTS & OTHER · MEDTECH | 406 | 400 | +1.5% |
| SPINE, SPORTS & OTHER · MEDTECH | 293 | 296 | -1.0% |
| SPINE, SPORTS & OTHER · MEDTECH | 698 | 696 | +0.3% |
| SPRAVATO · Innovative Medicine | 405 | 243 | +66.7% |
| SPRAVATO · Innovative Medicine | 53 | 42 | +26.2% |
| SPRAVATO · Innovative Medicine | 459 | 284 | +61.6% |
| STELARA · Innovative Medicine | 1,022 | 1,770 | -42.3% |
| STELARA · Innovative Medicine | 549 | 906 | -39.4% |
| STELARA · Innovative Medicine | 1,570 | 2,676 | -41.3% |
| SURGICAL · MEDTECH | 116 | 108 | +7.4% |
| SURGICAL · MEDTECH | 266 | 225 | +18.2% |
| SURGICAL · MEDTECH | 383 | 333 | +15.0% |
| TALVEY · Innovative Medicine | 85 | 64 | +32.8% |
| TALVEY · Innovative Medicine | 37 | 12 | +208.3% |
| TALVEY · Innovative Medicine | 122 | 75 | +62.7% |
| Tecvayli · Innovative Medicine | 115 | 105 | +9.5% |
| Tecvayli · Innovative Medicine | 62 | 30 | +106.7% |
| Tecvayli · Innovative Medicine | 177 | 135 | +31.1% |
| TRAUMA · MEDTECH | 512 | 497 | +3.0% |
| TRAUMA · MEDTECH | 281 | 265 | +6.0% |
| TRAUMA · MEDTECH | 793 | 761 | +4.2% |
| TREMFYA · Innovative Medicine | 989 | 691 | +43.1% |
| TREMFYA · Innovative Medicine | 434 | 316 | +37.3% |
| TREMFYA · Innovative Medicine | 1,424 | 1,007 | +41.4% |
| UPTRAVI · Innovative Medicine | 392 | 379 | +3.4% |
| UPTRAVI · Innovative Medicine | 92 | 80 | +15.0% |
| UPTRAVI · Innovative Medicine | 484 | 458 | +5.7% |
| XARELTO · Innovative Medicine | 635 | 592 | +7.3% |
| XARELTO · Innovative Medicine | 635 | 592 | +7.3% |
| ZYTIGA · Innovative Medicine | 5 | 5 | 0.0% |
| ZYTIGA · Innovative Medicine | 108 | 144 | -25.0% |
| ZYTIGA · Innovative Medicine | 113 | 150 | -24.7% |
Show Business Segments breakouts |
|||
| Innovative Medicine | 15,563 | 14,580 | +6.7% |
| Innovative Medicine · Cardiovascular / Metabolism / Other | 899 | 884 | +1.7% |
| Innovative Medicine · Immunology | 4,168 | 4,621 | -9.8% |
| Innovative Medicine · Infectious Diseases | 829 | 836 | -0.8% |
| Innovative Medicine · Neuroscience | 2,024 | 1,755 | +15.3% |
| Innovative Medicine · Non Us | 6,161 | 5,709 | +7.9% |
| Innovative Medicine · Non Us | 149 | 170 | -12.4% |
| Innovative Medicine · Non Us | 1,493 | 1,552 | -3.8% |
| Innovative Medicine · Non Us | 501 | 471 | +6.4% |
| Innovative Medicine · Non Us | 658 | 662 | -0.6% |
| Innovative Medicine · Non Us | 3,060 | 2,565 | +19.3% |
| Innovative Medicine · Non Us | 300 | 287 | +4.5% |
| Innovative Medicine · Oncology | 6,529 | 5,380 | +21.4% |
| Innovative Medicine · Operating Segments | 15,563 | 14,580 | +6.7% |
| Innovative Medicine · Pulmonary Hypertension | 1,115 | 1,102 | +1.2% |
| Innovative Medicine · US | 9,402 | 8,871 | +6.0% |
| Innovative Medicine · US | 750 | 713 | +5.2% |
| Innovative Medicine · US | 2,676 | 3,068 | -12.8% |
| Innovative Medicine · US | 326 | 365 | -10.7% |
| Innovative Medicine · US | 1,367 | 1,094 | +25.0% |
| Innovative Medicine · US | 3,468 | 2,816 | +23.2% |
| Innovative Medicine · US | 815 | 815 | 0.0% |
| MEDTECH | 8,430 | 7,891 | +6.8% |
| MEDTECH · ABIOMED | 423 | 362 | +16.9% |
| MEDTECH · Cardiovascular [Member] | 2,213 | 1,966 | +12.6% |
| MEDTECH · ELECTROPHYSIOLOGY | 1,418 | 1,279 | +10.9% |
| MEDTECH · Non Us | 4,124 | 3,853 | +7.0% |
| MEDTECH · Non Us | 86 | 68 | +26.5% |
| MEDTECH · Non Us | 908 | 819 | +10.9% |
| MEDTECH · Non Us | 698 | 619 | +12.8% |
| MEDTECH · Non Us | 878 | 832 | +5.5% |
| MEDTECH · Non Us | 65 | 66 | -1.5% |
| MEDTECH · Non Us | 59 | 66 | -10.6% |
| MEDTECH · Non Us | 1,511 | 1,451 | +4.1% |
| MEDTECH · Non Us | 828 | 751 | +10.3% |
| MEDTECH · Operating Segments | 8,430 | 7,891 | +6.8% |
| MEDTECH · Orthopaedics | 2,274 | 2,191 | +3.8% |
| MEDTECH · Other Cardiovascular | 95 | 96 | -1.0% |
| MEDTECH · Shockwave | 278 | 229 | +21.4% |
| MEDTECH · Surgery | 2,542 | 2,434 | +4.4% |
| MEDTECH · US | 4,306 | 4,038 | +6.6% |
| MEDTECH · US | 336 | 293 | +14.7% |
| MEDTECH · US | 1,306 | 1,148 | +13.8% |
| MEDTECH · US | 720 | 660 | +9.1% |
| MEDTECH · US | 1,396 | 1,359 | +2.7% |
| MEDTECH · US | 30 | 30 | 0.0% |
| MEDTECH · US | 220 | 163 | +35.0% |
| MEDTECH · US | 1,031 | 983 | +4.9% |
| MEDTECH · US | 571 | 549 | +4.0% |
| MEDTECH · Vision | 1,400 | 1,300 | +7.7% |
Show Geography breakouts |
|||
| Asia-Pacific, Africa | 3,614 | 3,475 | +4.0% |
| Europe | 5,440 | 4,914 | +10.7% |
| Non Us | 10,285 | 9,562 | +7.6% |
| US | 13,708 | 12,909 | +6.2% |
| Western Hemisphere, excluding U.S. | 1,231 | 1,173 | +4.9% |
| Sales Revenue Goods Net Percent To Sales | 100 | 100 | 0.0% |
| Cost of Revenue | 7,303 | 6,963 | +4.9% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 3,672 | 3,549 | +3.5% |
| MEDTECH · Operating Segments | 3,612 | 3,381 | +6.8% |
| Cost Of Goods Sold Percent To Sales | 30.4 | 31 | -1.9% |
| Gross Profit | 16,690 | 15,508 | +7.6% |
| Gross Profit Percent To Sales | 69.6 | 69 | +0.9% |
| Selling, General & Administrative | 5,922 | 5,478 | +8.1% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 2,869 | 2,491 | +15.2% |
| MEDTECH · Operating Segments | 2,801 | 2,723 | +2.9% |
| Selling General And Administrative Expense Percent To Sales | 24.7 | 24.3 | +1.6% |
| Research And Development Expense Excluding Acquired In Process Cost | 3,672 | 4,952 | -25.8% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 2,944 | 4,213 | -30.1% |
| MEDTECH · Operating Segments | 728 | 739 | -1.5% |
| Research And Development Expense Excluding Acquired In Process Cost Percent To Sales | 15.3 | 22 | -30.5% |
| Interest Income | -227 | -292 | +22.3% |
| Investment Income Interest Percent To Sales | -0.9 | -1.3 | +30.8% |
| Interest Expense | 245 | 193 | +26.9% |
| Interest Expense Percent To Sales | 1 | 0.9 | +11.1% |
| Other Non-Operating Income (Expense) | -478 | 1,798 | -126.6% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 368 | 155 | +137.4% |
| MEDTECH · Operating Segments | -2 | 11 | -118.2% |
| Other Non Operating Income Expense Percent To Sales | -2 | 8 | -125.0% |
| Restructuring Charges | 63 | 41 | +53.7% |
Show Business Segments breakouts |
|||
| MEDTECH | 0.2 | — | — |
| MedTech Surgery Franchise · Costs of Goods and Services Sold | 93 | — | — |
| MedTech Surgery Franchise · Operating Segments | 128 | — | — |
| MedTech Surgery Franchise · Restructuring Charges | 35 | — | — |
| MEDTECH · Costs of Goods and Services Sold | 12 | 6 | +100.0% |
| MEDTECH · Operating Segments | 40 | 28 | +42.9% |
| MEDTECH · Restructuring Charges | 28 | 22 | +27.3% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 168 | 47 | +257.4% |
| Restructuringchargepercenttosales | 0.3 | 0.2 | +50.0% |
| Income Before Taxes | 7,493 | 3,338 | +124.5% |
Show Business Segments breakouts |
|||
| Innovative Medicine · Operating Segments | 6,446 | 4,482 | +43.8% |
| MEDTECH · Operating Segments | 1,287 | 1,059 | +21.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 7,733 | 5,541 | +39.6% |
| Income Loss From Continuing Operations Before Income Taxes Noncontrolling Interest Percent To Sales | 31.2 | 14.9 | +109.4% |
| Income Tax Expense (Benefit) | 2,341 | 644 | +263.5% |
| Income Tax Expense Benefit Percent To Sales | 9.7 | 2.9 | +234.5% |
| Income Loss From Continuing Operations Net Of Tax Attributable To Parent Percent Of Sales | 21.5 | 12 | +79.2% |
| Net Income | 5,152 | 2,694 | +91.2% |
Show Equity Components breakouts |
|||
| Retained Earnings | 5,152 | 2,694 | +91.2% |
| EPS (Basic) | 2.14 | 1.12 | +91.1% |
| EPS (Diluted) | 2.12 | 1.11 | +91.0% |
| Wtd Avg Shares (Basic) | 2,408.3 | 2,407.2 | 0.0% |
| Wtd Avg Shares (Diluted) | 2,428.6 | 2,427.9 | 0.0% |
| Comprehensive Income | 4,220 | 1,425 | +196.1% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | 434 | 405 | +7.2% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 18,231 | 19,980 | -8.8% |
Show Information By Category Of Debt Security breakouts |
|||
| Availableforsale Securities | 3,494 | 3,619 | -3.5% |
| Availableforsale Securities · Corporate Debt Securities | 39 | 38 | +2.6% |
| Availableforsale Securities · Sovereign Debt Securities | 101 | — | — |
| Availableforsale Securities · US Treasury And Government | 3,354 | 3,581 | -6.3% |
| Heldtomaturity Securities | 14,737 | 16,361 | -9.9% |
| Heldtomaturity Securities · Bank Time Deposits | 879 | 1,183 | -25.7% |
| Heldtomaturity Securities · Cash | 3,097 | 3,328 | -6.9% |
| Heldtomaturity Securities · Money Market Funds | 5,298 | 4,848 | +9.3% |
| Heldtomaturity Securities · Securities Loaned Or Sold Under Agreements To Repurchase | 5,463 | 6,853 | -20.3% |
| Marketable Securities (Current) | 331 | 317 | +4.4% |
Show Information By Category Of Debt Security breakouts |
|||
| Availableforsale Securities | 331 | 199 | +66.3% |
| Availableforsale Securities · Corporate Debt Securities | 192 | 176 | +9.1% |
| Availableforsale Securities · Sovereign Debt Securities | 125 | 2 | +6150.0% |
| Availableforsale Securities · US Treasury And Government | 14 | 15 | -6.7% |
| Accounts Receivable | 17,611 | 16,174 | +8.9% |
| Inventory | 14,146 | 12,603 | +12.2% |
| Prepaid Expenses & Other Current Assets | 4,292 | 4,175 | +2.8% |
| Total Current Assets | 54,611 | 53,249 | +2.6% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 22,338 | 20,479 | +9.1% |
| Goodwill | 48,048 | — | — |
Show Business Segments breakouts |
|||
| Innovative Medicine | 14,268 | — | — |
| MEDTECH | 33,780 | — | — |
| Deferred Tax Assets | 6,666 | 9,349 | -28.7% |
| Other Non-Current Assets | 12,416 | 10,921 | +13.7% |
Show Fair Value By Asset Class breakouts |
|||
| Equity Securities · Equity Investments with readily determinable value | 573 | 505 | +13.5% |
| Equity Securities · Equity Investments without readily determinable value | 879 | 772 | +13.9% |
| Total Assets | 192,816 | — | — |
Show Business Segments breakouts |
|||
| General Corporate · Corporate Non Segment | 31,892 | — | — |
| Innovative Medicine · Operating Segments | 74,422 | — | — |
| MEDTECH · Operating Segments | 86,502 | — | — |
| Segments Total | 160,924 | — | — |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Other Intangible Assets | 6,469 | 7,209 | -10.3% |
| Patents And Trademarks | 22,687 | 18,227 | +24.5% |
| Marketable Securities (Non-Current) (Q) | — | — | — |
Show Fair Value By Asset Class breakouts |
|||
| Equity Securities · Equity Investments with readily determinable value | 573 | 505 | +13.5% |
| Other Assets | |||
| Property Plant And Equipment Gross | 53,375 | 49,274 | +8.3% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | -31,037 | -28,795 | -7.8% |
| Intangible Assets Net Excluding Goodwill | 48,737 | 39,490 | +23.4% |
| Current Liabilities | |||
| Short Term Borrowings | 6,387 | 4,462 | +43.1% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 6,387 | 4,462 | +43.1% |
| Estimate Of Fair Value Fair Value Disclosure | 6,373 | 4,429 | +43.9% |
Show Short Term Debt Type breakouts |
|||
| Commercial Paper | 4.4 | 2 | +120.0% |
| Accounts Payable | 9,625 | 8,954 | +7.5% |
| Accrued Liabilities | 7,601 | 11,450 | -33.6% |
| Accrued Rebates Returns And Promotions | 21,356 | 18,439 | +15.8% |
| Employee Related Liabilities Current | 3,972 | 3,620 | +9.7% |
| Accrued Income Taxes Current | 1,928 | 4,834 | -60.1% |
| Total Current Liabilities | 50,869 | 51,759 | -1.7% |
| Non-Current Liabilities | |||
| Long-Term Debt | 39,408 | 31,289 | +25.9% |
Show Debt Instrument breakouts |
|||
| 0.95% Notes due 2027 · Carrying Reported Amount Fair Value Disclosure | 1,498 | 1,463 | +2.4% |
| 0.95% Notes due 2027 · Estimate Of Fair Value Fair Value Disclosure | 1,426 | 1,389 | +2.7% |
| 1.150% Notes due 2028 (750MM Euro 1.1704) · Carrying Reported Amount Fair Value Disclosure | 875 | 832 | +5.2% |
| 1.150% Notes due 2028 (750MM Euro 1.1704) · Estimate Of Fair Value Fair Value Disclosure | 848 | 797 | +6.4% |
| 1.30% Notes due 2030 · Carrying Reported Amount Fair Value Disclosure | 1,694 | 1,671 | +1.4% |
| 1.30% Notes due 2030 · Estimate Of Fair Value Fair Value Disclosure | 1,546 | 1,522 | +1.6% |
| 1.650% Notes due 2035 (1.5B Euro 1.1704) · Carrying Reported Amount Fair Value Disclosure | 1,745 | 1,660 | +5.1% |
| 1.650% Notes due 2035 (1.5B Euro 1.1704) · Estimate Of Fair Value Fair Value Disclosure | 1,525 | 1,492 | +2.2% |
| 2.10% Notes due 2040 · Carrying Reported Amount Fair Value Disclosure | 903 | 885 | +2.0% |
| 2.10% Notes due 2040 · Estimate Of Fair Value Fair Value Disclosure | 703 | 726 | -3.2% |
| 2.25% Notes due 2050 · Carrying Reported Amount Fair Value Disclosure | 870 | 859 | +1.3% |
| 2.25% Notes due 2050 · Estimate Of Fair Value Fair Value Disclosure | 602 | 648 | -7.1% |
| 2.45% Notes due 2060 · Carrying Reported Amount Fair Value Disclosure | 1,120 | 1,107 | +1.2% |
| 2.45% Notes due 2060 · Estimate Of Fair Value Fair Value Disclosure | 709 | 782 | -9.3% |
| 2.700% Notes Due February 2029 · Carrying Reported Amount Fair Value Disclosure | 701 | — | — |
| 2.700% Notes Due February 2029 · Estimate Of Fair Value Fair Value Disclosure | 707 | — | — |
| 2.90% Notes due 2028 · Carrying Reported Amount Fair Value Disclosure | 1,498 | 1,497 | +0.1% |
| 2.90% Notes due 2028 · Estimate Of Fair Value Fair Value Disclosure | 1,473 | 1,465 | +0.5% |
| 2.95% Notes due 2027 · Carrying Reported Amount Fair Value Disclosure | 969 | 943 | +2.8% |
| 2.95% Notes due 2027 · Estimate Of Fair Value Fair Value Disclosure | 989 | 984 | +0.5% |
| 3.050% Notes Due February 2033 · Carrying Reported Amount Fair Value Disclosure | 817 | — | — |
| 3.050% Notes Due February 2033 · Estimate Of Fair Value Fair Value Disclosure | 822 | — | — |
| 3.20% Notes due 2032 (700MM Euro 1.0721) · Carrying Reported Amount Fair Value Disclosure | 816 | 776 | +5.2% |
| 3.20% Notes due 2032 (700MM Euro 1.0721) · Estimate Of Fair Value Fair Value Disclosure | 832 | 805 | +3.4% |
| 3.35% Notes Due 2036 (800MM Euro 1.0721) · Carrying Reported Amount Fair Value Disclosure | 931 | 886 | +5.1% |
| 3.35% Notes Due 2036 (800MM Euro 1.0721) · Estimate Of Fair Value Fair Value Disclosure | 933 | 914 | +2.1% |
| 3.350% Notes Due February 2037 · Carrying Reported Amount Fair Value Disclosure | 1,168 | — | — |
| 3.350% Notes Due February 2037 · Estimate Of Fair Value Fair Value Disclosure | 1,156 | — | — |
| 3.40% Notes due 2038 · Carrying Reported Amount Fair Value Disclosure | 994 | 993 | +0.1% |
| 3.40% Notes due 2038 · Estimate Of Fair Value Fair Value Disclosure | 877 | 897 | -2.2% |
| 3.50% Notes due 2048 · Carrying Reported Amount Fair Value Disclosure | 744 | 744 | 0.0% |
| 3.50% Notes due 2048 · Estimate Of Fair Value Fair Value Disclosure | 582 | 628 | -7.3% |
| 3.55% Notes Due 2044 (1.0B Euro 1.0721) · Carrying Reported Amount Fair Value Disclosure | 1,160 | 1,104 | +5.1% |
| 3.55% Notes Due 2044 (1.0B Euro 1.0721) · Estimate Of Fair Value Fair Value Disclosure | 1,127 | 1,140 | -1.1% |
| 3.587% Notes due 2036 · Carrying Reported Amount Fair Value Disclosure | 923 | 902 | +2.3% |
| 3.587% Notes due 2036 · Estimate Of Fair Value Fair Value Disclosure | 914 | 936 | -2.4% |
| 3.600% Notes Due February 2045 · Carrying Reported Amount Fair Value Disclosure | 814 | — | — |
| 3.600% Notes Due February 2045 · Estimate Of Fair Value Fair Value Disclosure | 787 | — | — |
| 3.625% Notes due 2037 · Carrying Reported Amount Fair Value Disclosure | 1,414 | 1,395 | +1.4% |
| 3.625% Notes due 2037 · Estimate Of Fair Value Fair Value Disclosure | 1,359 | 1,393 | -2.4% |
| 3.700% Notes Due February 2055 · Carrying Reported Amount Fair Value Disclosure | 1,164 | — | — |
| 3.700% Notes Due February 2055 · Estimate Of Fair Value Fair Value Disclosure | 1,094 | — | — |
| 3.73% Notes due 2046 · Carrying Reported Amount Fair Value Disclosure | 1,979 | 1,978 | +0.1% |
| 3.73% Notes due 2046 · Estimate Of Fair Value Fair Value Disclosure | 1,637 | 1,747 | -6.3% |
| 3.75% Notes due 2047 · Carrying Reported Amount Fair Value Disclosure | 884 | 868 | +1.8% |
| 3.75% Notes due 2047 · Estimate Of Fair Value Fair Value Disclosure | 814 | 873 | -6.8% |
| 4.375% Notes due 2033 · Carrying Reported Amount Fair Value Disclosure | 853 | 854 | -0.1% |
| 4.375% Notes due 2033 · Estimate Of Fair Value Fair Value Disclosure | 859 | 879 | -2.3% |
| 4.50% Notes due 2027 · Carrying Reported Amount Fair Value Disclosure | 749 | — | — |
| 4.50% Notes due 2027 · Estimate Of Fair Value Fair Value Disclosure | 760 | — | — |
| 4.50% Notes due 2040 · Carrying Reported Amount Fair Value Disclosure | 542 | 541 | +0.2% |
| 4.50% Notes due 2040 · Estimate Of Fair Value Fair Value Disclosure | 532 | 553 | -3.8% |
| 4.50% Notes due 2043 · Carrying Reported Amount Fair Value Disclosure | 496 | 496 | 0.0% |
| 4.50% Notes due 2043 · Estimate Of Fair Value Fair Value Disclosure | 472 | 501 | -5.8% |
| 4.55% Notes Due 2029 · Carrying Reported Amount Fair Value Disclosure | 748 | — | — |
| 4.55% Notes Due 2029 · Estimate Of Fair Value Fair Value Disclosure | 764 | — | — |
| 4.70% Notes due 2030 · Carrying Reported Amount Fair Value Disclosure | 996 | — | — |
| 4.70% Notes due 2030 · Estimate Of Fair Value Fair Value Disclosure | 1,030 | — | — |
| 4.80% Notes due 2029 · Carrying Reported Amount Fair Value Disclosure | 1,146 | 1,146 | 0.0% |
| 4.80% Notes due 2029 · Estimate Of Fair Value Fair Value Disclosure | 1,185 | 1,198 | -1.1% |
| 4.85% Notes Due 2032 · Carrying Reported Amount Fair Value Disclosure | 1,243 | — | — |
| 4.85% Notes Due 2032 · Estimate Of Fair Value Fair Value Disclosure | 1,297 | — | — |
| 4.85% Notes due 2041 · Carrying Reported Amount Fair Value Disclosure | 298 | 297 | +0.3% |
| 4.85% Notes due 2041 · Estimate Of Fair Value Fair Value Disclosure | 299 | 313 | -4.5% |
| 4.90% Notes due 2031 · Carrying Reported Amount Fair Value Disclosure | 1,146 | 1,146 | 0.0% |
| 4.90% Notes due 2031 · Estimate Of Fair Value Fair Value Disclosure | 1,198 | 1,215 | -1.4% |
| 4.95% Notes due 2033 · Carrying Reported Amount Fair Value Disclosure | 499 | 499 | 0.0% |
| 4.95% Notes due 2033 · Estimate Of Fair Value Fair Value Disclosure | 521 | 536 | -2.8% |
| 4.95% Notes due 2034 · Carrying Reported Amount Fair Value Disclosure | 847 | 846 | +0.1% |
| 4.95% Notes due 2034 · Estimate Of Fair Value Fair Value Disclosure | 892 | 904 | -1.3% |
| 5.00% Notes due 2035 · Carrying Reported Amount Fair Value Disclosure | 1,244 | — | — |
| 5.00% Notes due 2035 · Estimate Of Fair Value Fair Value Disclosure | 1,297 | — | — |
| 5.25% Notes due 2054 · Carrying Reported Amount Fair Value Disclosure | 843 | 843 | 0.0% |
| 5.25% Notes due 2054 · Estimate Of Fair Value Fair Value Disclosure | 865 | 921 | -6.1% |
| 5.85% Notes due 2038 · Carrying Reported Amount Fair Value Disclosure | 697 | 697 | 0.0% |
| 5.85% Notes due 2038 · Estimate Of Fair Value Fair Value Disclosure | 774 | 804 | -3.7% |
| 5.95% Notes due 2037 · Carrying Reported Amount Fair Value Disclosure | 995 | 994 | +0.1% |
| 5.95% Notes due 2037 · Estimate Of Fair Value Fair Value Disclosure | 1,116 | 1,157 | -3.5% |
| 6.95% Notes due 2029 · Carrying Reported Amount Fair Value Disclosure | 299 | 298 | +0.3% |
| 6.95% Notes due 2029 · Estimate Of Fair Value Fair Value Disclosure | 333 | 344 | -3.2% |
| Other · Carrying Reported Amount Fair Value Disclosure | 86 | 71 | +21.1% |
| Other · Estimate Of Fair Value Fair Value Disclosure | 85 | 71 | +19.7% |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 39,408 | 31,289 | +25.9% |
| Estimate Of Fair Value Fair Value Disclosure | 37,741 | 30,496 | +23.8% |
| Deferred Tax Liabilities | 5,988 | 2,952 | +102.8% |
| Employee Related Liabilities Current And Noncurrent | 6,930 | 6,852 | +1.1% |
| Accrued Income Taxes Noncurrent | 418 | 354 | +18.1% |
| Other Non-Current Liabilities | 9,926 | 14,923 | -33.5% |
| Total Liabilities | 113,539 | 108,129 | +5.0% |
| Stockholders' Equity | |||
| Common Stock | 3,120 | 3,120 | 0.0% |
| Accumulated Other Comprehensive Income | -15,237 | -12,522 | -21.7% |
| Retained Earnings | 167,281 | 155,179 | +7.8% |
| Treasury Stock Common Value | 75,887 | 75,619 | +0.4% |
| Total Stockholders' Equity | 79,277 | 70,158 | +13.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 79,277 | 70,158 | +13.0% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -1,419 | -1,930 | +26.5% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -346 | -641 | +46.0% |
| Accumulated Net Unrealized Investment Gain Loss | 0 | 1 | -100.0% |
| Accumulated Other Comprehensive Income | -15,237 | -12,522 | -21.7% |
| Accumulated Translation Adjustment | -13,472 | -9,952 | -35.4% |
| Common Stock | 3,120 | 3,120 | 0.0% |
| Retained Earnings | 167,281 | 155,179 | +7.8% |
| Treasury Stock Common | -75,887 | -75,619 | -0.4% |
| Total Liabilities & Equity | 192,816 | 178,287 | +8.1% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 5,492 | 5,443 | +0.9% |
Show Business Segments breakouts |
|||
| General Corporate · Corporate Non Segment | 171 | 280 | -38.9% |
| Innovative Medicine · Operating Segments | 2,757 | 2,793 | -1.3% |
| MEDTECH · Operating Segments | 2,564 | 2,370 | +8.2% |
| Segments Total | 5,321 | 5,163 | +3.1% |
| Stock-Based Compensation | 1,045 | 938 | +11.4% |
| Asset Impairment Charges | 123 | 379 | -67.5% |
| In Process Research And Development Charge | 109 | 1,252 | -91.3% |
| Gain Loss On Sales Of Assets And Asset Impairment Charges | -131 | -225 | +41.8% |
| Deferred Income Taxes | 5,215 | -2,167 | +340.7% |
| Provision For Doubtful Accounts | -6 | -11 | +45.5% |
| Change in Accounts Receivable | -2,172 | -1,259 | -72.5% |
| Change in Inventory | -1,404 | -1,038 | -35.3% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 1,111 | 2,713 | -59.0% |
| Increase Decrease In Other Operating Assets | -7,653 | 949 | -906.4% |
| Increase Decrease In Other Operating Liabilities | -6,196 | -326 | -1800.6% |
| Net Cash from Operations | 17,221 | 17,283 | -0.4% |
| Investing Activities | |||
| Capital Expenditures | -2,995 | -2,812 | -6.5% |
| Proceeds From Sale Of Productive Assets | 408 | 623 | -34.5% |
| Payments To Acquire Businesses Net Of Cash Acquired | -14,459 | -15,145 | +4.5% |
| Payments To Acquire In Process Research And Development Assets | -385 | -1,250 | +69.2% |
| Payments To Acquire Investments | -677 | -1,464 | +53.8% |
| Proceeds From Sale Maturity And Collections Of Investments | 1,442 | 2,172 | -33.6% |
| Proceeds Payments From To Credit Support Agreements Investing Activities | -2,338 | 699 | -434.5% |
| Other Investing Activities | -99 | -102 | +2.9% |
| Net Cash from Investing | -19,103 | -17,279 | -10.6% |
| Financing Activities | |||
| Payments Of Ordinary Dividends | -9,250 | -8,839 | -4.6% |
| Share Repurchases | -4,029 | -2,150 | -87.4% |
| Proceeds From Short Term Debt | 10,673 | 11,984 | -10.9% |
| Repayments Of Short Term Debt | -10,524 | -8,354 | -26.0% |
| Proceeds From Issuance Of Long Term Debt | 9,138 | 6,660 | +37.2% |
| Repayments Of Senior Debt | -1,755 | -804 | -118.3% |
| Proceeds From Exercise Of Stock Options And Excess Tax Benefits | 1,831 | 714 | +156.4% |
| Proceeds Payments From To Credit Support Agreements Financing Activities | -246 | 5 | -5020.0% |
| Proceeds From Payments For Other Financing Activities | -8 | -38 | +78.9% |
| Net Cash from Financing | -4,170 | -1,792 | -132.7% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 178 | -91 | +295.6% |
| Net Change in Cash | -5,874 | -1,879 | -212.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 18,231 | 19,980 | -8.8% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.